Leonardo O Rodrigues

Dr. Leonardo O Rodrigues

Olaris, Inc
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2022 in Metabolites
Verified
Journal Article
Open access
PDF file
CDChen Dong
Chen Dong
CHChandra Honrao
Chandra Honrao
LRLeonardo O Rodrigues
Leonardo O Rodrigues
JWJosephine Wolf
Josephine Wolf
KSKeri Sanborn Sheehan
Keri Sanborn Sheehan
Elizabeth ODayElizabeth ODay
Elizabeth ODay
Parkinson’s disease (PD) is a progressive neurodegenerative disease, causing loss of motor and nonmotor function. Diagnosis is based on clinical symptoms that do not develop until late in the disease progression, at which point the majority of the patients’ dopaminergic neurons are already destroyed. While many PD cases are idiopathic, hereditable genetic risks have been identified, including mutations in the gene for LRRK2, a multidomain kinase with roles in autophagy, mitochondrial function, transcription, molecular structural integrity, the endo-lysosomal system, and the immune response. A definitive PD diagnosis can only be made post-mortem, and no noninvasive or blood-based disease biomarkers are currently available. Alterations in metabolites have been identified in PD patients, suggesting that metabolomics may hold promise for PD diagnostic tools. In this study, we sought to identify metabolic markers of PD in plasma. Using a 1H-13C heteronuclear single quantum coherence spectroscopy (HSQC) NMR spectroscopy metabolomics platform coupled with machine learning (ML), we measured plasma metabolites from approximately age/sex-matched PD patients with G2019S LRRK2 mutations and non-PD controls. Based on the differential level of known and unknown metabolites, we were able to build a ML model and develop a Biomarker of Response (BoR) score, which classified male LRRK2 PD patients with 79.7% accuracy, 81.3% sensitivity, and 78.6% specificity. The high accuracy of the BoR score suggests that the metabolomics/ML workflow described here could be further utilized in the development of a confirmatory diagnostic for PD in larger patient cohorts. A diagnostic assay for PD will aid clinicians and their patients to quickly move toward a definitive diagnosis, and ultimately empower future clinical trials and treatment options.

1 December 2025 in Cancer Research Communications
Verified
Journal Article
Open access
VSVivek Subbiah
Vivek Subbiah
PYPeter P. Yu
Peter P. Yu
RSRangaprasad Sarangarajan
Rangaprasad Sarangarajan
MKMichael Kiebish
Michael Kiebish
LRLeonardo O Rodrigues
Leonardo O Rodrigues
Madappa N. KundrandaMadappa N. Kundranda
Madappa N. Kundranda
Purpose: BPM31510IV, a highly bioavailable intravenously administered coenzyme Q10 (CoQ10) formulation, was evaluated in a phase Ia/Ib study as monotherapy and in combination with chemotherapy in patients with advanced solid tumors. Patients and Methods: Using a 3 + 3 design, patients received twice-weekly intravenous infusions of BPM31510IV monotherapy (arm 1) or combined with gemcitabine, 5-fluorouracil/leucovorin, or docetaxel (arm 2); crossover between arms was permitted. Tumor response was assessed by RECIST1.1. Pharmacokinetic and multiomics pharmacodynamic (PD) analyses were performed on plasma and core biopsy samples. Results: A total of 97 patients were enrolled, 33 in arm 1 and 71 in arm 2 (seven patients crossed from arm 1 to arm 2). The MTD was 171 mg/kg for BPM31510IV monotherapy or with 5-fluorouracil/leucovorin and 110 mg/kg with gemcitabine or docetaxel. Four dose-limiting toxicities occurred (two in monotherapy; two in combination with chemotherapy). Most adverse events were coagulation-related, occurring in 96% of patients (grade ≥3 in 4%). Pharmacokinetics showed dose-proportional increases in CoQ10 levels to supraphysiologic concentrations (>200×). In arm 1, there was one (3%) partial response (PR), with stable disease (SD) reported in eight (24%) patients. In arm 2, there was one (1%) PR, with SD reported in 25 (35%) patients. Fluorodeoxyglucose-PET imaging and PD data suggest a change in tumor metabolism from glycolysis to oxidative phosphorylation. Conclusions: BPM31510IV as monotherapy and in combination with chemotherapy was safe, with preliminary evidence of antitumor activity. High plasma CoQ10 levels were achieved, inducing PD responses consistent with mitochondrial metabolic changes. These findings support continued clinical development of BPM31510IV. Significance: BPM31510IV is a lipid nanodispersion of oxidized CoQ10 that alters the Warburg effect and displays anticancer activity. BPM31510IV seems to synergize with chemotherapy to induce cancer cell apoptosis, likely through mitochondrial priming. An initial phase I monotherapy study demonstrated that BPM31510IV is well tolerated in patients with advanced solid tumors. Based on these observations, the safety and preliminary antitumor activity of BPM31510IV were further explored in a phase Ia/Ib study in combination with chemotherapy. Results indicated that BPM31510IV monotherapy and BPM31510IV combined with chemotherapy are well tolerated, demonstrating preliminary evidence of antitumor activity and inducing physiologic and molecular changes consistent with altered mitochondrial metabolism. The most common adverse events were changes in coagulation parameters. Overall, this study provides valuable MTD and surrogate efficacy data that support the continued clinical development of BPM31510IV.

24 December 2025
Verified
Other
Open access
VSVivek Subbiah
Vivek Subbiah
PYPeter P. Yu
Peter P. Yu
RSRangaprasad Sarangarajan
Rangaprasad Sarangarajan
MKMichael Kiebish
Michael Kiebish
LRLeonardo O Rodrigues
Leonardo O Rodrigues
Madappa N. KundrandaMadappa N. Kundranda
Madappa N. Kundranda
Kaplan–Meier curves showing median progression-free survival for patients in each dosing cohort and treatment arm.

24 December 2025
Verified
Other
Open access
VSVivek Subbiah
Vivek Subbiah
PYPeter P. Yu
Peter P. Yu
RSRangaprasad Sarangarajan
Rangaprasad Sarangarajan
MKMichael Kiebish
Michael Kiebish
LRLeonardo O Rodrigues
Leonardo O Rodrigues
Madappa N. KundrandaMadappa N. Kundranda
Madappa N. Kundranda
Best response to BPM31510IV patients who had at least one tumor imaging assessment at or following Cycle 2.

24 December 2025
Verified
Other
Open access
VSVivek Subbiah
Vivek Subbiah
PYPeter P. Yu
Peter P. Yu
RSRangaprasad Sarangarajan
Rangaprasad Sarangarajan
MKMichael Kiebish
Michael Kiebish
LRLeonardo O Rodrigues
Leonardo O Rodrigues
Madappa N. KundrandaMadappa N. Kundranda
Madappa N. Kundranda
Serious adverse events (SAEs) attributed by the Investigator to the study treatment.

24 December 2025
Verified
Other
Open access
VSVivek Subbiah
Vivek Subbiah
PYPeter P. Yu
Peter P. Yu
RSRangaprasad Sarangarajan
Rangaprasad Sarangarajan
MKMichael Kiebish
Michael Kiebish
LRLeonardo O Rodrigues
Leonardo O Rodrigues
Madappa N. KundrandaMadappa N. Kundranda
Madappa N. Kundranda
Metabolites detected in plasma or urine that correlate with systemic protein changes. Further information on the column names is provided in the Patients and Methods and the legend for Table S13.